Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) VP Nathalie Adda sold 13,453 shares of the firm’s stock in a transaction that occurred on Friday, October 8th. The shares were sold at an average price of $70.09, for a total transaction of $942,920.77. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Nathalie Adda also recently made the following trade(s):
- On Monday, October 11th, Nathalie Adda sold 4,047 shares of Enanta Pharmaceuticals stock. The stock was sold at an average price of $70.34, for a total transaction of $284,665.98.
Shares of ENTA stock opened at $69.64 on Thursday. Enanta Pharmaceuticals, Inc. has a 12-month low of $40.32 and a 12-month high of $72.00. The firm has a fifty day moving average of $55.88 and a 200-day moving average of $50.29. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -16.78 and a beta of 0.43.
Large investors have recently added to or reduced their stakes in the stock. The PNC Financial Services Group Inc. increased its position in Enanta Pharmaceuticals by 42.8% during the first quarter. The PNC Financial Services Group Inc. now owns 787 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 236 shares during the period. Royal Bank of Canada boosted its stake in shares of Enanta Pharmaceuticals by 1,367.7% in the 2nd quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 1,313 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 103.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,601 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 814 shares in the last quarter. Eaton Vance Management acquired a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $115,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $201,000.
A number of brokerages have issued reports on ENTA. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Monday. JMP Securities lifted their target price on shares of Enanta Pharmaceuticals from $70.00 to $77.00 and gave the stock an “outperform” rating in a report on Friday, August 6th. SVB Leerink began coverage on shares of Enanta Pharmaceuticals in a report on Thursday, September 9th. They issued a “market perform” rating and a $55.00 target price on the stock. Jefferies Financial Group began coverage on shares of Enanta Pharmaceuticals in a report on Wednesday, October 6th. They set a “buy” rating and a $95.00 price objective on the stock. Finally, Royal Bank of Canada dropped their price objective on shares of Enanta Pharmaceuticals from $52.00 to $50.00 and set a “sector perform” rating on the stock in a report on Friday, August 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Hold” and an average price target of $68.50.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.
See Also: Market Timing
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.